XSHE
300497
Market cap1.47bUSD
Oct 09, Last price
18.43CNY
1D
1.04%
1Q
0.60%
Jan 2017
21.37%
IPO
337.04%
Name
Jiangxi Fushine Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
8.40
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.44%
Rev. gr., 5y
-3.73%
Revenues
1.18b
+0.35%
Net income
0
P
CFO
63m
-66.60%
Dividend
Aug 24, 20260.05 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangxi Fushine Pharmaceutical Co., Ltd. is engaged in the global research, development, production, and marketing of active pharmaceutical ingredients (APIs) and key chemical compounds for drug synthesis. Its product portfolio includes important antibiotics like penicillin and carbapenem, alongside a variety of other pharmaceutical offerings. The company also extends its expertise by providing contract research, development, and manufacturing services. Founded in 2002 and headquartered in Jingdezhen, China, the firm was initially named Jingdezhen Fuxiang Pharmaceutical Co., Ltd. before adopting its current designation in August 2012.
Key people
Jizu Cheng
Executive President, Director · since 2025
Huiyue Li
Vice Chairman of the Board · since 2023
Guang Yang
Chief Financial Officer (Finance Director) · since 2022
Zhenliang Dai
Deputy General Manager · since 2016
Ying Liu
Executive Deputy General Manager · since 2019
Luyuan Liu
Deputy General Manager · since 2021
Haipeng Wei
Deputy General Manager · since 2022
Xiangming Zhang
Deputy General Manager · since 2012
Yun Peng
Deputy General Manager, Secretary of the Board · since 2022
Jianhua Bao
Chairman of the Board · since 2022
Rongwu Cheng
Director · since 2019
Dan Ke
Vice President, Director · since 2024
Xiaoqing Ji
Independent Director · since 2023
Yan Li
Independent Director · since 2020
Hong Liu
Independent Director · since 2021
Headquarters & legal address
江西省景德镇市昌江区鱼丽工业区2号（鱼山与丽阳交界处）
景德镇市, JX 333000
CN
景德镇市, JX 333000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||